P0018FS
doi:10.1016/j.spen.2013.10.008CrossRefGoogle ScholarPubMed Krhenbhl, S, Brandner, S, Kleinle, S, Liechti, S, Straumann, D
Contrave's clinical development program, anchored by the COR trials, presents more moderate efficacy data
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
doi:10.1080/13554790802368661CrossRefGoogle ScholarPubMed Narayanan, A, White, CA, Saklayen, S, et al
It must be considered that multiple factors interact to control IGF-1 levels, many of which are disturbed in T2D, namely: increased inflammatory cytokines, decreased hepatic insulin action due to resistance, concomitant changes in IGFBPs, and the effects of obesity